Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,265
archived clinical trials in
Rheumatoid Arthritis

A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Danbury, CT
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Danbury, CT
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Trumbull, CT
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Trumbull, CT
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Lewes, DE
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Lewes, DE
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Boynton Beach, FL
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Naples, FL
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Naples, FL
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
New Port Richey, FL
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
New Port Richey, FL
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Orlando, FL
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Palm Harbor, FL
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Palm Harbor, FL
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Tampa, FL
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Vernon Hills, IL
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Vernon Hills, IL
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Indianapolis, IN
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Kalamazoo, MI
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Lansing, MI
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Lansing, MI
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Columbia, MO
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Columbia, MO
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Las Vegas, NV
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Freehold, NJ
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Freehold, NJ
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Toms River, NJ
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Toms River, NJ
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Albany, NY
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Albany, NY
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Hartsdale, NY
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Hartsdale, NY
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Asheville, NC
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Asheville, NC
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Charlotte, NC
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Middleburg Heights, OH
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Middleburg Heights, OH
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Tulsa, OK
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Tulsa, OK
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Portland, OR
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Bethlehem, PA
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Bethlehem, PA
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Wyomissing, PA
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Wyomissing, PA
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Myrtle Beach, SC
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Cypress, TX
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Cypress, TX
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Dallas, TX
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Lubbock, TX
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Lubbock, TX
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Nassau Bay, TX
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Nassau Bay, TX
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Webster, TX
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Webster, TX
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Chesapeake, VA
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Chesapeake, VA
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Kennewick, WA
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Kennewick, WA
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Vancouver, WA
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Vancouver, WA
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Franklin, WI
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Franklin, WI
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Saint Louis, MO
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
mi
from
Buenos Aires,
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
mi
from
Buenos Aires,
Click here to add this to my saved trials
A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494
A Study in Healthy Adult Volunteers and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability, and Pharmacokinetics After Multiple Dosing of ABT-494
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Miami, FL
A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494
A Study in Healthy Adult Volunteers and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability, and Pharmacokinetics After Multiple Dosing of ABT-494
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494
A Study in Healthy Adult Volunteers and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability, and Pharmacokinetics After Multiple Dosing of ABT-494
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Duncansville, PA
A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494
A Study in Healthy Adult Volunteers and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability, and Pharmacokinetics After Multiple Dosing of ABT-494
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Duncansville, PA
Click here to add this to my saved trials
A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494
A Study in Healthy Adult Volunteers and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability, and Pharmacokinetics After Multiple Dosing of ABT-494
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Austin, TX
A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494
A Study in Healthy Adult Volunteers and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability, and Pharmacokinetics After Multiple Dosing of ABT-494
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494
A Study in Healthy Adult Volunteers and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability, and Pharmacokinetics After Multiple Dosing of ABT-494
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Cincinnati, OH
A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494
A Study in Healthy Adult Volunteers and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability, and Pharmacokinetics After Multiple Dosing of ABT-494
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494
A Study in Healthy Adult Volunteers and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability, and Pharmacokinetics After Multiple Dosing of ABT-494
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Orem, UT
A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494
A Study in Healthy Adult Volunteers and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability, and Pharmacokinetics After Multiple Dosing of ABT-494
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Orem, UT
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-122 in Subjects With Rheumatoid Arthritis
A Study in Patients With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ABT-122
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Lenexa, KA
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-122 in Subjects With Rheumatoid Arthritis
A Study in Patients With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ABT-122
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Lenexa, KA
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-122 in Subjects With Rheumatoid Arthritis
A Study in Patients With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ABT-122
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Raleigh, NC
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-122 in Subjects With Rheumatoid Arthritis
A Study in Patients With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ABT-122
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-122 in Subjects With Rheumatoid Arthritis
A Study in Patients With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ABT-122
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Duncansville, PA
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-122 in Subjects With Rheumatoid Arthritis
A Study in Patients With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ABT-122
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Duncansville, PA
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-122 in Subjects With Rheumatoid Arthritis
A Study in Patients With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ABT-122
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Dallas, TX
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-122 in Subjects With Rheumatoid Arthritis
A Study in Patients With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ABT-122
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
An Open-label, International, Multi-center, Phase II, Extension Trial Investigating Long-term Efficacy and Safety of Repeated Treatment Courses of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Adult Patients With Active Rheumatoid Arthritis Who Previously Received Ofatumumab or Placebo
Status: Enrolling
Updated:  11/27/2017
GSK Investigational Site
mi
from
Los Angeles, CA
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
An Open-label, International, Multi-center, Phase II, Extension Trial Investigating Long-term Efficacy and Safety of Repeated Treatment Courses of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Adult Patients With Active Rheumatoid Arthritis Who Previously Received Ofatumumab or Placebo
Status: Enrolling
Updated: 11/27/2017
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
An Open-label, International, Multi-center, Phase II, Extension Trial Investigating Long-term Efficacy and Safety of Repeated Treatment Courses of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Adult Patients With Active Rheumatoid Arthritis Who Previously Received Ofatumumab or Placebo
Status: Enrolling
Updated:  11/27/2017
GSK Investigational Site
mi
from
Fort Lauderdale, FL
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
An Open-label, International, Multi-center, Phase II, Extension Trial Investigating Long-term Efficacy and Safety of Repeated Treatment Courses of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Adult Patients With Active Rheumatoid Arthritis Who Previously Received Ofatumumab or Placebo
Status: Enrolling
Updated: 11/27/2017
GSK Investigational Site
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
An Open-label, International, Multi-center, Phase II, Extension Trial Investigating Long-term Efficacy and Safety of Repeated Treatment Courses of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Adult Patients With Active Rheumatoid Arthritis Who Previously Received Ofatumumab or Placebo
Status: Enrolling
Updated:  11/27/2017
GSK Investigational Site
mi
from
New York, NY
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
An Open-label, International, Multi-center, Phase II, Extension Trial Investigating Long-term Efficacy and Safety of Repeated Treatment Courses of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Adult Patients With Active Rheumatoid Arthritis Who Previously Received Ofatumumab or Placebo
Status: Enrolling
Updated: 11/27/2017
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials